Cellectis (CLLS) Free Cash Flow Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 66.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.98% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 137.65% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 9.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.66% |
| Dec 31, 2025 | -162.51% |
| Sep 30, 2025 | 92.28% |
| Jun 30, 2025 | -118.80% |
| Mar 31, 2025 | 27.41% |
| Dec 31, 2024 | -110.96% |
| Sep 30, 2024 | 69.89% |
| Jun 30, 2024 | 383.48% |
| Mar 31, 2024 | 17.84% |
| Sep 30, 2023 | 34.44% |
| Jun 30, 2023 | 17.13% |
| Mar 31, 2023 | -327.52% |
| Sep 30, 2022 | 0.84% |
| Jun 30, 2022 | -239.39% |
| Mar 31, 2022 | 40.41% |
| Sep 30, 2021 | -33.93% |
| Jun 30, 2021 | 19.04% |
| Mar 31, 2021 | -217.77% |
| Dec 31, 2020 | -248.13% |
| Sep 30, 2020 | -12.18% |
| Jun 30, 2020 | 54.74% |
| Mar 31, 2020 | 145.52% |
| Dec 31, 2019 | -9.98% |
| Sep 30, 2019 | -24.69% |
| Jun 30, 2019 | -51.89% |
| Mar 31, 2019 | -6.42% |
| Dec 31, 2018 | -101.53% |
| Sep 30, 2018 | 7.57% |
| Jun 30, 2018 | 26.83% |
| Mar 31, 2018 | -22.89% |
| Dec 31, 2017 | 44.04% |
| Sep 30, 2017 | -2,698.31% |
| Jun 30, 2017 | -104.38% |
| Mar 31, 2017 | -10.09% |
| Dec 31, 2016 | -187.00% |
| Sep 30, 2016 | 111.67% |
| Jun 30, 2016 | 53.99% |
| Mar 31, 2016 | -929.31% |